protein
| tubulin |
|
inhibition of caspase 3 and caspase 7, SMAC releasing the inhibition of caspase |
|
XPO1 (CRM1) for nuclear export |
|
binding the catalytic domain of aurora B (AURKB) |
|
interaction between survivin and aurora-B kinase may be essential for survivin to increase TERT expression |
|
binding of TP53, a repressor of survivin expression, and DNA methylation inhibits TP53-mediated survivin repression |
|
BCL2L1 and BIRC5 can critically contribute in a cooperative, nonredundant manner to augment the accumulation and persistence of CD8(+) T cells following encounter with Antigen |
|
interacting with PLK1 (interact during mitosis and PLK1 phosphorylates survivin at serine 20, which is essential for accurate chromosome alignment and cell proliferation but is dispensable for its anti-apoptotic activity in cancer cells) |
|
physiological substrate for GZMM (GZMM hydrolyzes Survivin at Leu-138 to remove the last four C-terminal residues) |
|
interaction between BECN1 and BIRC5 affects the sensitivity of human glioma cells to TNFSF10-induced apoptosis |
|
AIP-TOMM20 recognition contributes to cell survival in development and cancer by mediating the mitochondrial import of BIRC5 |
|
in apoptosis, BIRC5 recognize the DIABLO protein |
|
YAP1, CTNNB1 and TBX5 form a complex that regulates the expression of genes that promote survival, including BIRC5 and BCL2L1 |
|
SOX2 directly up-regulates the expression of BIRC5, which inhibits the mitochondria-dependent apoptotic pathway in NSCs (neural stem cells) |
|
depletion of KRAS promotes proteasome degradation of BIRC5 (PMID |
|
GSPT1 interact with BIRC5 through the N-terminal domain (NTD: residues 131-200) |
|
cooperation between MYCN and BIRC5 may be important in the genesis of several cancers |
|
BIRC5 partially regulates HSC function by modulating the MECOM transcription factor and its downstream targets and identify new genetic pathways in HSCs regulated by BIRC5 |
|
BIRC5 expression promotes VEGFA-induced tumor angiogenesis via PI3K/Akt enhanced CTNNB1/HNF4A-LEF1 dependent transcription |
|
protects pancreatic beta-cells against ER stress-mediated apoptosis by up-regulating BIRC5 expression and down-regulating DDIT3 expression, which we termed as "positive and negative regulation |
|
TP53RK signaling pathway promotes colon cancer metastasis by modulating BIRC5 stability |
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --other
|  
|
disturbed expression of BIRC5 and EPR1 in hematological malignancy (in acute myeloid leukemia with unfavourable prognostic factor) | tumoral
|  
|  
| --over
|  
|
with TERT in soft tissue sarcoma with very poor outlook, and in stomach tumor cell nuclei (with favorable prognosis) | constitutional
|  
|  
| --over
|  
|
in endometriosis | tumoral
|  
|  
| --over
|  
|
in uterus cancer,panceas, colon, gastric, breast, prostate adenocarcinomas, in alveolar rhabdomyosarcoma | tumoral
|  
|  
|  
| gain of function
|
in esophageal cancer | tumoral
|  
|  
| --low
|  
|
silencing promotes XIAP degradation and enhances GZMM-induced caspase activation as well as GZMM- and NK cell-induced cytolysis of target tumor cells | tumoral
|  
|  
| --over
|  
|
in the majority of non-small cell lung carcinoma, together with the abundant or upregulated expression of HBXIP and XIAP suggest that tumours are endowed with resistance against a variety of apoptosis-inducing conditions | tumoral
|  
|  
| --over
|  
|
overexpression of FOXM1, XIAP, and BIRC5 contributes to the development of drug-resistance and is associated with poor clinical outcome in breast cancer patients | |